RxDoctor Payments Data

Jon Stauffer, MD

Gastroenterology · Rockport, MENPI 1194720177

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,280 of the $6,734 with a category attached, or 78.4%. 22 manufacturers reported payments, led by AbbVie at 31.1% of the total.

$6,734in general payments, 2019–2025

Across 331 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Covidien LP$1K
  • Johnson & Johnson$946
  • Boston Scientific$551
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$464
  • Takeda Pharmaceuticals U.S.A., Inc.$326
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,45422%
  • Food & beverage$5,28078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,734 in reported general payments places this provider in the 80th percentile of 68 gastroenterology providers in Maine.

See all gastroenterology providers in Maine

Medicare billing

Part B allowed, 2024
$198,747
Medicare patients
328
Services billed
4,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$11,926
Esomeprazole Magnesium78$5,466
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates77$4,923
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,059
Pantoprazole Sodium150$1,925
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg83$1,618
Famotidine205$1,395
Omeprazole99$1,147
Sucralfate21$619
Metronidazole22$136
Ondansetron OdtOndansetron13$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,091$11,92611 claims
Ferring Pharmaceuticals Inc.Clenpiq$30$2,05912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 gastroenterology providers in Maine.

Other gastroenterology in Rockport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →